Indian Pharma News

US tariffs may not immediately affect Indian pharmaceutical companies, but building manufacturing capacity in the US remains expensive for them, while a Deloitt

Experts are advising the Indian pharmaceutical industry to diversify globally and prioritize innovation in response to proposed US pharma tariffs. This strategi

Donald Trump has threatened a 200% tariff on generic drugs entering the United States after a two-year period of zero tariffs, which Indian pharma warns would i

Donald Trump's plan to bring drug manufacturing back to the US includes imposing zero tariffs on imported generics for two years, followed by increases to 100%

Donald Trump's proposed generic drug tariffs offer Indian drugmakers a two-year duty-free period to adjust manufacturing and supply chain strategies before sign

Donald Trump has threatened 200% tariffs on generic drugs by 2028, aiming to move manufacturing to the US, which caused a "kneejerk reaction" in Indian pharma s